ADVFN Logo ADVFN
시장 데이터
뉴스
도구
시장
팔로우

Hot Features

피드 팔로우

Follow Feed 커뮤니티에서 거래자 및 투자자와 연결하세요.

실시간 옵션 플로우

포괄적인 옵션 데이터를 탐색하고 옵션 흐름으로 고급 필터를 사용하세요.

모니터

터미널 모니터로 주식 및 자산 관심 목록을 구성하고 모니터링하세요.
로그인 Premium Icon프리미엄 Help Menu
S&P 500
5,035.69
-1.57%
US Tech 100
16,927.18
-2.21%
다우존스 지수
37,815.92
-1.49%
Bitcoin
60,159.94
-5.76%
Registration Strip Icon for charts 실시간 차트, 분석 도구 및 가격을 받으려면 등록하세요.
등록
  1. 홈
  2. 인베스팅
  3. 주식
  4. 미국
  5. NASDAQ
  6. Amarin Corp PLC (AMRN)

  7. Amarin Corp PLC (AMRN) 뉴스

AMRN Amarin Corp PLC

0.89
0.013 (1.48%)
시간외 거래
최종 업데이트: 06:05:19
15분 지연
기업명 주식 심볼 시장 주식 타입
Amarin Corp PLC AMRN 나스닥 주식예탁증서 (DR)
  가격 변동 가격 변동 % 주식 가격 최근 거래 시간
Upgrade Icon
0.013 1.48% 0.89 06:05:19
개장가 저가 고가 종가 전일 종가
0.884 0.8692 0.9289 0.9209 0.877
시세 정보 더보기 »

최근 뉴스

일자 시간 출처 제목
25/04/202403:00GLOBEAmarin Applauds HealthyWomen’s Citizen’s Petition Urging FDA..
22/04/202421:00GLOBEAmarin Announces Results of Annual General Meeting of..
15/04/202421:00GLOBEAmarin to Report First Quarter 2024 Financial Results and..
08/04/202421:00GLOBEAmarin Highlights Key Data Providing Mechanistic Insights..
08/04/202419:30PRNCANew REDUCE-IT® Analyses Show VASCEPA® (Icosapent Ethyl)..
07/04/202404:30GLOBENew REDUCE-IT® Analyses Show VASCEPA®/VAZKEPA® (Icosapent..
03/04/202421:00GLOBEAmarin Provides Update on VAZKEPA® (Icosapent Ethyl)..
25/03/202421:00GLOBEResearch Evaluating Benefits of VASCEPA®/VAZKEPA® (icosapent..
05/03/202407:30EDGAR2Form ARS - Annual Report to Security Holders
04/03/202422:00EDGAR2Form DEF 14A - Other definitive proxy statements
29/02/202421:06EDGAR2Form 10-K - Annual report [Section 13 and 15(d), not S-K..
29/02/202421:05EDGAR2Form 8-K - Current report
29/02/202421:00GLOBEAmarin Reports Fourth Quarter and Full Year 2023 Financial..
15/02/202422:00GLOBEAmarin to Report Fourth Quarter and Full Year 2023 Financial..
12/02/202422:00EDGAR2Form PRE 14A - Other preliminary proxy statements
10/02/202406:31EDGAR2Form 4 - Statement of changes in beneficial ownership of..
10/02/202406:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
10/02/202406:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
03/02/202406:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
03/02/202406:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
03/02/202406:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
26/01/202421:00EDGAR2Form 8-K - Current report
25/01/202406:31EDGAR2Form 4 - Statement of changes in beneficial ownership of..
22/01/202421:30GLOBEAmarin Chairman & CEO Issue Letter to Shareholders
13/01/202407:31EDGAR2Form 4 - Statement of changes in beneficial ownership of..
13/01/202407:27EDGAR2Form 4 - Statement of changes in beneficial ownership of..
13/01/202407:25EDGAR2Form 4 - Statement of changes in beneficial ownership of..
10/01/202421:00EDGAR2Form 8-K - Current report
10/01/202421:00GLOBEAmarin Provides Preliminary Fourth Quarter 2023 Selected..
09/01/202408:03EDGAR2Form 4 - Statement of changes in beneficial ownership of..
09/01/202408:03EDGAR2Form 4 - Statement of changes in beneficial ownership of..
03/01/202406:47EDGAR2Form 4 - Statement of changes in beneficial ownership of..
03/01/202406:43EDGAR2Form 4 - Statement of changes in beneficial ownership of..
15/12/202308:35EDGAR2Form 4 - Statement of changes in beneficial ownership of..
13/12/202306:20EDGAR2Form 144 - Report of proposed sale of securities
11/12/202322:00GLOBEAmarin to Present at the 42nd Annual J.P. Morgan Healthcare..
06/12/202306:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/12/202321:30EDGAR2Form SC 13D/A - General statement of acquisition of..
12/11/202323:00GLOBENew REDUCE-IT® Analyses Show VASCEPA® (icosapent ethyl)..
04/11/202305:30EDGAR2Form 8-K - Current report
01/11/202320:05EDGAR2Form 8-K - Current report
01/11/202320:05EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
01/11/202320:00GLOBEAmarin Reports Third Quarter 2023 Financial Results
01/11/202305:05EDGAR2Form 8-K - Current report
01/11/202301:00GLOBEAmarin Appoints Jonathan Provoost Executive Vice President,..
26/10/202321:00GLOBELatest Research Evaluating VASCEPA®/VAZKEPA® (icosapent..
19/10/202321:00GLOBE Amarin to Report Third Quarter 2023 Financial Results and..
12/09/202321:00GLOBEAmarin to Present at the 2023 Cantor Global Healthcare..
06/09/202305:15EDGAR2Form SC 13D/A - General statement of acquisition of..
17/08/202308:51EDGAR2Form 4 - Statement of changes in beneficial ownership of..

최근 히스토리

NASDAQ
AMRN
Amarin
Delayed Upgrade Clock
ADVFN Logo

대한변국
회사 소개
사업
Popular
앱 받기

도움 및 지원받기: kr-support@advfn.com

ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관

© 2024 ADVFN PLC - 모든 권리 보유